Découvrez le nouveau Chem-Impex : là où l'innovation commence par une liaison.

Catalog Number:
38252
CAS Number:
103628-48-4
Succinate de sumatriptan
Purity:
97,5 - 102,0 % (HPLC)
Synonym(s):
3-[2-(diméthylamino)éthyl]-1 H -indol-5-yl- N -méthylméthanesulfonamidesuccinate
Documents
$40.00 /100 mg
Taille
Request Bulk Quote
Informations sur le produit

Sumatriptan succinate is a potent pharmaceutical compound primarily used in the treatment of acute migraine attacks. As a selective agonist for serotonin receptors, it effectively alleviates migraine symptoms by constricting dilated blood vessels in the brain, thereby reducing inflammation and pain. This compound is particularly beneficial for patients who experience severe migraines, providing rapid relief and improving quality of life. Its unique formulation allows for various delivery methods, including oral tablets and injectable forms, catering to diverse patient needs and preferences.

In addition to its primary use in migraine therapy, Sumatriptan succinate has shown potential in research settings, particularly in studies exploring the mechanisms of migraine pathophysiology. Its efficacy and safety profile make it a preferred choice among healthcare professionals. With a well-established history of use, Sumatriptan succinate stands out in the realm of migraine treatments, offering a reliable option for those seeking effective relief from debilitating headaches.

Numéro CAS 
103628-48-4
Formule moléculaire
C14H21N3O2S · C4H6O4
Poids moléculaire 
413.49
Point de fusion 
165 - 169 °C (lit.)
Informations générales
Numéro CAS 
103628-48-4
Formule moléculaire
C14H21N3O2S · C4H6O4
Poids moléculaire 
413.49
Point de fusion 
165 - 169 °C (lit.)
Propriétés
Informations complémentaires sur la propriété à venir prochainement !
-
Sécurité et réglementation
Matières dangereuses
-
Antibiotique
-
Réglementé par la DEA
Non
Avertissements 
-
Applications

Sumatriptan succinate is widely utilized in research focused on

  • Migraine Treatment: This compound is primarily used in the pharmaceutical industry for the treatment of acute migraine attacks, providing rapid relief to patients by constricting blood vessels in the brain.
  • Clinical Research: Sumatriptan succinate is often involved in clinical trials aimed at evaluating new migraine therapies, helping researchers understand its efficacy and safety compared to other treatments.
  • Combination Therapies: In some cases, it is studied in combination with other medications to enhance therapeutic outcomes for patients with chronic migraines, offering a more comprehensive approach to pain management.
  • Pharmacokinetic Studies: Researchers utilize this compound to investigate its absorption, distribution, metabolism, and excretion (ADME) properties, which are crucial for developing new formulations and delivery methods.
  • Patient Compliance Research: Sumatriptan succinate is also examined in studies that assess patient adherence to treatment regimens, providing insights into how formulation changes can improve user experience and outcomes.

Citations